Late Breaking Clinical Trials Submission is now Open

ESTS proudly invites the submission of Late Breaking Clinical Trial Abstracts for the 34th Meeting in Athens. This category is exclusively reserved for high-impact, practice-changing data.

We are seeking randomized clinical trials, large-scale population studies, and groundbreaking translational evidence. This is your opportunity to submit an abstract that stands at the forefront of thoracic innovation and, if accepted, present your findings to the global thoracic community.

Deadline: 24 March at Midnight CET

Submit your Late Breaking Clinical Trial Here

Submission Guidelines

  1. Breaking Clinical Trial abstracts are targeted towards randomized clinical trial data, large population-based trial evidence, or novel translational evidence that is likely to
    be highly cited and impactful in clinical practice.
  2. Retrospective investigations or metanalyses will not be considered.
  3. Exempt from publication in EJCTS
  4. Previously presented data can be submitted for consideration, but this will be reviewed by the Program Committee and assessed for suitability to present.
  5. The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission.
  6. The presenting author must be listed as the first author.
  7. All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
  8. Please submit symbols as words.
  9. All abstracts accepted for a presentation will be published on the Meeting website prior to the Meeting.
  10. Please note the presenting author will receive all correspondence about the abstract so we advise that the submitting author details that are entered are the same details as those of the presenting author.
  11. Abstracts may not be edited/updated after final submission.
  12. Your abstract is not successfully submitted until you receive a confirmation e-mail after clicking the final submit button. If you do not receive a confirmation e-mail, please contact us.
  13. Company or product names are not allowed in the title

Abstract Format

Context:
Objective:
Design, Setting, Participants:
Interventions:
Main Outcome Measure:
Results:
Conclusions:
Trial Registration:
Funding:
Maximum 300 words and two tables